WorksheetsBiphasic Aspart Quiz
Total questions: 31
Worksheet time: 13mins
As per IDF date 2019, among top 10 countries with diabetics (20-79 years), Pakistan is at position _________.
10th
6th
8th
4th
What is the number of diabetics in Pakistan (20-79 years), as per IDF data - 2019?
18 Million
19.4 Million
10 Million
15.4 Million
Novomix® 30 got US approval in _________.
2001
1999
2000
When Novomix® 30 is launched in Pakistan?
2002
2004
2006
2008
When Novomix® 50 is launched in Pakistan?
2012
2013
2014
2015
Insulin aspart differs from human insulin by the single amino-acid substitution of a ____________ by an aspartic acid residue at _______.
Glycine, B26
Proline, B28
Asparginine, B26
Lysine, B28
The B28 position is implicated in the formation of ____________ but not implicated in pharmacological activity of insulin.
Monomers
Dimers
Hexamers
When NovoMix® 30 is injected subcutaneously, the onset of action will occur within __________ minutes of injection.
10 - 15
10 - 20
15
5 - 10
1ml of NovoMix® 30 contains ____ units of insulin aspart/protaminated aspart in 70/30 ratio that is equivalent to ____mg.
200, 3.5
300, 3.0
100, 3.5
100, 3.0
When using BIAsp 30 once daily switch to twice daily, when reaching _____ units, split the dose into equal breakfast and dinner doses.
20
30
40
50
If twice daily dosing results in recurrent daytime hypoglycemic episodes, breakfast dose can be split into breakfast & lunch?
True
False
NovoMix® 30 can be used in children aged below 10 years?
True
False
There are restrictions on treatment with NovoMix® during lactation.
True
False
Switching from basal-plus/basal-bolus to
premix insulin
Reduce the total insulin dose (basal + mealtime insulin) by 10% to 20%
No dose adjustment needed
Increase the total insulin dose (basal + mealtime insulin) by 10%
Reduce the total insulin dose (basal + mealtime insulin) by 20% to 30%
Switching from basal-plus/basal-bolus to
premix insulin - Split the resulting dose into;
BID – for patients switching from BASAL-PLUS
TID – for patients switching from BASAL-BOLUS
OD – for patients switching from BASAL-PLUS
TID – for patients switching from BASAL-BOLUS
BID – for patients switching from BASAL-PLUS
BID – for patients switching from BASAL-BOLUS
OD – for patients switching from BASAL-PLUS
BID – for patients switching from BASAL-BOLUS
Intensifying from BIAsp BID to TID
Add 20% of total daily BIAsp 30 dose
before lunch
Add 15% of total daily BIAsp 30 dose
before lunch
Add 10% of total daily BIAsp 30 dose
before lunch
Add 5% of total daily BIAsp 30 dose
before lunch
Insulin intensification guidelines for switch from BIAsp 30 to BIAsp 50 is 1:1 dose transfer.
True
False
Improve was Multinational, open-label, 6-month observational study involving 46,000 pts from 13 countries including Pakistan.
True
False
A1chieve was Multinational, open-label, 6-month observational study involving greater than 66,000 pts from 28 countries including Pakistan.
True
False
In patients with type 2 diabetes, a dose reduction of _________ is recommended for patients with an HbA1c less than 8% when a GLP-1 receptor agonist is added to NovoMix® 30, to minimise the risk of hypoglycaemia.
10%
20%
25%
15%
The maximum serum insulin concentration is, on average, _________ higher with NovoMix® 30 than with biphasic human insulin 30.
30%
20%
40%
50%
The priming for the new pen of NovoMix 30® should not be done more than _______, if a drop of insulin doesn't appear, pen is defective and should be discarded.
2 time
3 times
7 times
6 times
The other name of Strojek et al is ____________.
1 2 3 Study
OnceMix
EasyMix
Initiate
In initiate Study, NovoMix 30® is administered ____________.
Once Daily
Twice Daily
Thrice Daily
The other name of Garber et al is ___________.
Sit2Mix
1 2 3 Study
EasyMix
OnceMix
The other name of A1chive is ____________.
Gupta et al
Home at al
El Naggar et al
Lithem et al
Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes. Which Study is this?
Linjawi et al
Hermanson et al
Davidson et al
Raskin et al
Safety and efficacy of biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) were compared with once-daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs (OADs). Which study is this?
Rys et al
Davidson et al
Raskin et al
Garbar et al
Efficacy and safety of once-daily biphasic insulin aspart 70/30 (BIAsp 30) with sitagliptin and twice-daily BIAsp 30 with or without sitagliptin in patients with
type 2 diabetes. Which study is this?
Sit2Mix
1 2 3 Study
Initiate
EasyMix
Risk for Nocturnal Hypoglycemia With Biphasic Insulin
Aspart 30 Compared With Biphasic Human Insulin 30 in
Adults With Type 2 Diabetes Mellitus. Which study is this?
Hermensan et al
Jacobson et al
Heise et al
Davidson et al
For Novomix®, always check there are at least _______ units of insulin left in the cartridge to allow re-suspension. If
there are less than the specified units left, use a new FlexPen®.
10
12
15
18
